Patent: 7,405,237
✉ Email this page to a colleague
Summary for Patent: 7,405,237
Title: | Isoindoline compounds and methods of their use |
Abstract: | Novel isoindoline compounds are disclosed. Methods of treating, preventing and/or managing cancer, diseases and disorders associated with, or characterized by, undesired angiogenesis, and diseases and disorders mediated by PDE 4, using the compounds are also disclosed. |
Inventor(s): | Muller; George W. (Bridgewater, NJ), Man; Hon-Wah (Princeton, NJ) |
Assignee: | Celgene Corporation (Summit, NJ) |
Application Number: | 10/900,332 |
Patent Claims: | see list of patent claims |
Details for Patent 7,405,237
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2039-02-26 |
Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | ⤷ Try a Trial | 2039-02-26 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2039-02-26 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |